Aktieanalys

Sedana Medical Q3: Pushing the US one year (again) - Redeye

Redeye Publicerad: 24 Oct 11:58

Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too optimistic), and we are curious about its development into Q4 as the company raises its 2024e sales target to 17-20% CER (from 14-18%). Still, the report has some considerable heavy news: the FDA recommends Sedana to integrate the European trial’s data into the US submission. This pushes the US submission timeline by one year and adds roughly SEK20-30m in costs. Naturally, this will be devastating for the share today, and we expect it to drop by 30-40%.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045748/sedana-medical-q3-pushing-the-us-one-year-again?utm_source=finwire&utm_medium=RSS

Nyheter om Sedana Medical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!